Targeting KAT2A/B with an Oral Heterobifunctional Degrader for Heme Malignancies & Inflammatory Diseases

4:30 pm - Tuesday 27th October 2026

  • AUTX-703 is in phase 1 development for hematological malignancies
  • AUTX-163 for inflammatory diseases

Speakers:

Katharine Yen
Founder & Chief Executive Officer
Auron Therapeutics